There are variations in DNA that determine the susceptibility to develop a disease, abbreviated as SNPs. Recently, researchers at Dartmouth University found three SNPs that could be potential biomarkers. If proven, these three SNPs could be the key to unlock the precision with which researchers categorize risk of lung cancer by smoking behavior. This research could go a long way in giving individualized prognoses and appropriately predicting treatment plans. This is an unconventional angle to approach lung cancer. Studies into genetics to investigate the etiology of different cancers are a cause taken up by few like Tempus.
Endeavoring to Create Molecular Maps
Technology has influenced human lives greatly. However, healthcare is still pretty behind in the use of technology. Tempus was started to establish an operating system to assist in battling cancer. Armed with almost 100 of some of the brightest minds on in the field of medicine and IT, Tempus seeks to aid physicians in getting a full dimensional understanding of tumors. The organization does most of its work in a 20,000 square foot genomics laboratory. It is the belief of Tempus co-founder, Eric Lefkofsky that with a full understanding of the tumors being treated, a more personalized and effective treatment plan can be developed. Tempus collects data from all over. The company uses genomic sequencing and analysis methods. All this data is entered into a database that is made available to physicians. From this information, they can compare their own patients with others for a better understanding. Tempus is attempting to secure a future where cancer patients can get tailor-made medication and care for longer and better quality lives.
Giving and More Giving
Eric Lefkofsky attended the University of Michigan for his studies. He and his wife started the Lefkofsky Family Foundation in 2006. The charitable foundation is geared towards advancing high impact initiatives that enhance lives. Eric and Liz Lefkofsky have donated to many cancer research programs. This is a testament to their commitment to the improvement of cancer care by all means necessary. The couple has pledged to leave half their wealth to charity upon passing. By constantly questioning conventional thinking and collaborating with other groups with similar interests, Eric Lefkofsky is on a quest to decrease the number of patients diagnosed every year. His devotion to the cause is unstoppable; he will not rest until healthcare sector experiences real revolution.